Eledon Pharmaceuticals shares surge 10.07% intraday as company partners with NewcelX to develop combination therapy for type 1 diabetes using NCEL-101 and tegoprubart.

Eledon Pharmaceuticals surged 10.07% intraday, announcing a strategic collaboration with NewcelX to combine NCEL-101 (a stem cell-derived islet project) with its anti-CD40L antibody tegoprubart for a type 1 diabetes combination therapy. The partnership aims to enable durable immune protection for islet replacement and a potential functional cure. Eledon, a clinical-stage immunology company focused on transplant medicine, develops immune-modulating therapies targeting the CD40L pathway, including tegoprubart for preventing transplant rejection and treating diseases.